Abstract: Methods, systems and apparatus, including computer programs encoded on computer storage media, for training a policy neural network by repeatedly updating the policy neural network at each of a plurality of training iterations. One of the methods includes generating training data for the training iteration by controlling the agent in accordance with an improved policy that selects actions in response to input state representations. A best response computation is performed using (i) a candidate policy generated from respective policy neural networks as of one or more preceding iterations and (ii) a candidate value neural network. The candidate value neural network is configured to generate a value output that is an estimate of a value of the environment being in the state characterized by a state representation to complete a particular task. The policy neural network is updated by training the policy neural network on the training data.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for controlling agents. In particular, an agent can be controlled using a policy neural network that has been trained to allow the agent to achieve cultural transmission after training.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-05 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: Methods, systems and apparatus, including computer programs encoded on computer storage media, for training a policy neural network by repeatedly updating the policy neural network at each of a plurality of training iterations. One of the methods includes generating training data for the training iteration by controlling the agent in accordance with an improved policy that selects actions in response to input state representations. A best response computation is performed using (i) a candidate policy generated from respective policy neural networks as of one or more preceding iterations and (ii) a candidate value neural network. The candidate value neural network is configured to generate a value output that is an estimate of a value of the environment being in the state characterized by a state representation to complete a particular task. The policy neural network is updated by training the policy neural network on the training data.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease.

Abstract: The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease.

Abstract: The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease.

Abstract: An nstrumented thoracic model for measuring the effects of impacts is provided. The model has simulated skeletal components, simulated tissue, simulated internal organs, and sensors that are optimally placed in the simulated tissue and organs, said simulated organs and said simulated skeletal components. Simulated human tissue is made of a modified ballistic gelatin, comprising ordinance gelatin, chilled water and an antimicrobial agent in a desired volume or weight percentage. The resulting mixture is then poured into a container or mold having the desired tissue shape, and then chilled until the mixture has set. Simulated lung tissue is made of the modified ballistic gelatin, but also incorporates nicrospheres to approximate the density and modality of the lungs.

Abstract: A bicycle trailer hitch assembly including first and second complementary hitch bracket members adapted and arranged for attachment to opposites sides of the bicycle frame rear wheel drop out. Each bracket member includes a main body portion configured on one side for abutting relation with the bicycle rear wheel drop out and on the other side for receiving the trailer tongue tube to provide center pulling of the trailer. The bicycle quick release skewer which holds the rear wheel clamped to the drop out member likewise secures both brackets to the drop out member. Each of the brackets has a fastener arrangement for enabling securing the bracket to the trailer drawbar.

Abstract: A seat for a collapsible jogging stroller, or the like, that does not require removal prior to collapsing of the stroller. A bar member, unattached to the stroller frame, is located at the juncture of the seating and leg rest portions of the seat and extends transversely across the seat to provide lateral support to the seat. Being unattached to the frame of the stroller the bar member does not impede or obstruct collapsing of the stroller. The seat is formed of a one-piece flexible cloth-like material that is simple and inexpensive to manufacture.

Abstract: A bicycle brake shoe assembly including multiple brake pads of different braking compounds replaceably inserted sequentially into a truncated pad holder. The pads have an overlap at one end and an under-lap at the other end such that upon assembly within the holder an overlap portion is mated over an under-lap portion. The pads are captured and retained in place in the truncated holder by a removable end cap. The overlap/under-lap pad mating cooperates with the pad holder and end cap to prevent pad pull out because of wheel rim movement forces on the pads. The brake shoe assembly has a transverse curvature substantially in conformance with the radius of curvature of the bicycle wheel rim, thereby improving pad contact with the wheel rim.